Mr. David Scheer is the founder and President of Scheer & Company, which provides strategic and transactional advisory services to companies in the life sciences industry. Mr. Scheer brings decades of experience to OrphAI Therapeutics, having founded, built and advised multiple biotechnology companies, including Achillion, Viropharma, OraPharma and the original Esperion Therapeutics which were cumulatively acquired for nearly $7 Billion. Mr. Scheer is Chairman of the Boards of BiologicsMD, Inc., Adela, Inc., and Refactor Health. Amongst his additional advisory roles, Mr. Scheer serves as a member of the Board of Directors of BioCT and as a member of the Bioscience Innovation Advisory Committee, which oversees investments made by the $200M Connecticut Bioscience Innovation Fund. He has had significant experience in the orphan space, not only advancing innovator companies but also advising important not-for-profit entities, notably including the National Organization for Rare Disorders (NORD). He has served as a founding member of CUPA (Compassionate Use and Preapproval Access Working Group, affiliated with the Bioethics Division of NYU), member of the Impact Council of the Rutgers Global Health Institute, Vice-Chair of the Board of the Global Virus Network, and has been involved in a series of initiatives in the global health space during his tenure as a volunteer advisor for the Harvard T.H. Chan School of Public Health. Mr. Scheer holds an A.B. degree cum laude in Biochemical Sciences from Harvard College and an M.S. degree in Cell, Molecular and Developmental Biology from Yale University.
